42.84 USD
▲-0.07+10.24%
盘后 38.34 -1.34%
2026-08-03
市值
$7.32B
市盈率
—
EPS
-2.51
股息率
—
52 周区间
10.38 – 43.73
成交量
4.75M
Beta
0.33
目标价
54.25
52W 低 10.3852W 高 43.73
价格走势
公司简介
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a rev...